Emerging retatrutide, a dual -action drug targeting both GLP-1 and GIP receptors, is creating considerable interest within the weight loss website community. Early clinical studies have revealed substantial losses in physical size and improvements in physiological markers for people with obesity . Scientists believe this ground-breaking approach co